Treatment of chronic myeloid leukemia with imatinib mesylate

International Journal of Clinical Oncology

Volumn 11, Issue 3, 2006, Pages 176-183

  Ohno, Ryuzo ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Allogeneic stem cell transplantation; BCR ABL; Chronic myeloid leukemia; Imatinib mesylate; Tyrosine kinase inhibitor

Indexed keywords

ABELSON KINASE; ADENOSINE TRIPHOSPHATE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BUSULFAN; CYTARABINE; DASATINIB; HYDROXYUREA; IMATINIB; NILOTINIB; NS 187; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANAMNESIS; APOPTOSIS; BINDING SITE; BLAST CELL CRISIS; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CAUSE OF DEATH; CELL FUNCTION; CELL GROWTH; CHIMERA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMPETITIVE INHIBITION; CYTOGENETICS; CYTOPENIA; DEPRESSION; DIARRHEA; DONOR; DOSE CALCULATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EDEMA; FAMILY; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENE OVEREXPRESSION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; GROUPS BY AGE; GROWTH DISORDER; HLA MATCHING; HUMAN; IC 50; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; MULTIMODALITY CANCER THERAPY; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHILADELPHIA 1 CHROMOSOME; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SKIN DISEASE; STANDARD; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

COMBINED MODALITY THERAPY; DRUG RESISTANCE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 33746131219     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-006-0582-5     Document Type: Review

References (58)

1. PC Nowell DA Hungerford 1960 A minute chromosome in human granulocytic leukemia Science 132 1497 1497
2. JD Rowley 1973 A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining Nature 243 290 293
3. S Faderl M Talpaz Z Estrov 1999 The biology of chronic myeloid leukemia N Engl J Med 341 164 172
4. CL Sawyers 1999 Chronic myeloid leukemia N Engl J Med 340 1330 1340
5. MW Deininger JM Goldman JV Melo 2000 The molecular biology of chronic myeloid leukemia Blood 96 3343 3356
6. GQ Daley RA Van Etten D Baltimore 1990 Induction of chronic myelogenous leukemia in mice by the P210 bcr/abl gene of the Philadelphia chromosome Science 247 824 830
7. TG Lugo AM Pendergast AJ Muller 1990 Tyrosine kinase activity and transformation potency of bcr-abl oncogene products Science 247 1079 1082
8. J Cortes 2004 Natural history and staging of chronic myelogenous leukemia Hematol Oncol Clin North Am 18 569 584
9. G Garcia-Manero S Fader S O'Brien 2003 Chronic myelogenous leukemia: a review and update of therapeutic strategies Cancer 98 427 456
10. R Hehlmann U Berger A Hochhaus 2005 Chronic myeloid leukemia: a model for oncology Ann Hematol 84 487 497
11. R Hehlmann U Berger M Pfirrmann 2003 Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-Study II): prolongation of survival by the combination of interferon α and hydroxyurea Leukemia 17 1529 1537
12. HM Kantarjian T Smith S O'Brien 1995 Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy Ann Intern Med 122 254 261
13. K Ohnishi R Ohno M Tomonaga 1995 A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase Blood 86 906 916
14. K Ohnishi S Minami T Ueda 2000 Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia Int J Hematol 72 229 236
15. RP Gale R Hehlmann M-J Zhang 1998 Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia Blood 91 1810 1819
16. JA Hansen TA Gooley PJ Martin 1998 Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia N Engl J Med 338 962 968
17. ME Gorre M Mohammed K Ellwood 2002 Current trends in hematopoietic stem cell transplantation in Europe Blood 100 2374 2386
18. BJ Druker S Tamura E Buchdunger 1996 Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med 2 561 566
19. M Deininger E Buchdunger BJ Druker 2005 The development of imatinib as a therapeutic agent for chronic myeloid leukemia Blood 105 2640 2653
20. BJ Druker M Talpaz DJ Resta 2001 Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 1031 1037
21. B Peng M Hayes D Resta 2004 Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients J Clin Oncol 22 935 942
22. BJ Druker CL Sawyers H Kantarjian 2001 Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N Engl J Med 344 1038 1042
23. H Kantarjian C Sawyers A Hochhaus 2002 Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia N Engl J Med 346 645 652
24. M Talpaz RT Silver BJ Druker 2002 Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a Phase 2 study Blood 99 1928 1937
25. CL Sawyers A Hochhaus E Feldman 2002 Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a Phase II study Blood 99 3530 3539
26. OG Ottmann BJ Druker CL Sawyers 2002 A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias Blood 100 1965 1971
27. M Towatari M Yanada N Usui 2004 Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia Blood 104 3507 3512
28. M Yanada J Takeuchi I Sugiura 2006 High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group J Clin Oncol 24 460 466
29. Y Morishima M Ogura M Nishimura 2004 Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical study Int J Hematol 80 261 266
30. SG O'Brien F Guilhot RA Larson 2003 Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 348 994 1004
31. F Guilhot C Chastang M Michallet 1997 Interferon alpha-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia N Engl J Med 337 223 229
32. TP Hughes J Kaeda S Branford 2003 Frequency of major molecular responses to imatinib or interferon alpha plus cytarabine in newly diagnosed chronic myeloid leukemia N Engl J Med 349 1423 1432
33. EA Hahn GA Glendenning MV Sorensen 2003 Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alpha plus low-dose cytarabine: results from the IRIS Study J Clin Oncol 21 2138 2146
34. Simonsson B on behalf of the IRIS (International Randomized IFN vs STI571) Study Group 2005 Beneficial effects of cytogenetic and molecular response on long-term outcome in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM): Update from the IRIS Study Blood 106 52a (abstract 166)
35. HM Kantarjian S O'Brien J Cortes 2003 Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in the chronic phase: comparison with historic data Cancer 98 2636 2642
36. Shah NP (2005) Chronic myeloid leukemia; Loss of response to imatinib: mechanisms and management. Hematology (Am Soc Hematol Educ Program):183-187
37. ME Gorre M Mohammed K Ellwood 2001 Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 876 880
38. N von Bubnoff F Schneller C Peschel J Duyster 2002 BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study Lancet 359 487 491
39. S Branford Z Rudzki S Walsh 2002 High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance Blood 99 3472 3475
40. WK Hofmann S de Vos D Elashoff 2002 Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study Lancet 359 481 486
41. C Roche-Lestienne V Soenen-Cornu N Grardel-Duflos 2002 Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment Blood 100 1014 1018
42. NP Shah JM Nicoll B Nagar 2002 Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia Cancer Cell 2 117 125
43. A Hochhaus S Kreil AS Corbin 2002 Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy Leukemia 16 2190 2196
44. AS Corbin PL Rosee EP Stoffregen 2003 Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib Blood 101 4611 4614
45. HM Kantarjian M Talpaz S O'Brien 2003 Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia Blood 101 473 475
46. J Cortes F Giles S O'Brien 2003 Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-α Blood 102 83 86
47. NP Shah C Tran FY Lee 2004 Overriding imatinib resistance with a novel ABL kinase inhibitor Science 305 399 401
48. T O'Hare DK Walters EP Stoffregen 2005 In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants Cancer Res 65 4500 4505
49. E Weisberg PW Manley W Breitenstein 2005 Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Cancer Cell 7 129 141
50. S Kimura H Naito H Segawa 2005 NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia Blood 106 3948 3954
51. T Lange DW Niederwieser MW Deininger 2003 Residual disease in chronic myeloid leukemia after induction of molecular remission N Engl J Med 349 1483 1484
52. J Cortes S O'Brien H Kantarjian 2004 Discontinuation of imatinib therapy after achieving a molecular response Blood 104 2204 2205
53. JP Radich G Gehly T Gooley 1995 Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients Blood 85 2632 2638
54. Deininger MWN (2005) Chronic myeloid leukemia: management of early stage disease. Hematology (Am Soc Hematol Educ Program):174-182
55. JJ Molldrem PP Lee C Wang 2000 Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia Nat Med 6 1018 1023
56. A Burchert S Wolfl M Schmidt 2003 Interferon alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia Blood 101 259 264
57. OA Elisseeva Y Oka A Tsuboi 2002 Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies Blood 99 3272 3279
58. Y Kano M Akutsu S Tsunoda 2001 In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents Blood 97 1999 2007